Grupos de investigación

  1. Portada
  2. Publicaciones
  3. Publicaciones 2001-2003

Publicaciones 2001-2003

Publicaciones anteriores

  1. “Lymphocyte regulation of neuropeptide gene expression after neuronal injury”. Armstrong BD, Hu Z, Abad C, Yamamoto M, Rodríguez WI, Cheng J, Tam J, Gomariz RP, Patterson PH, Waschek JA. J Neurosci Res. 2003 Oct 15;74(2):240-7.
  2. “PACAP in immunity and inflammation”. Delgado M, Abad C, Martínez C, Juarranz MG, Leceta J, Ganea D, Gomariz RP. Ann N Y Acad Sci. 2003 May;992:141-57.
  3. “Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease”. Abad C, Martínez C, Juarranz MG, Arranz A, Leceta J, Delgado M, Gomariz RP. Gastroenterology. 2003 Apr;124(4):961-71.
  4. “Pituitary adenylate-cyclase-activating polypeptide expression in the immune system”. Abad C, Martínez C, Leceta J, Juarranz MG, Delgado M, Gomariz RP. Neuroimmunomodulation. 2002-2003;10(3):177-86.
  5. “Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia”. Delgado M, Leceta J, Ganea D. J Leukoc Biol. 2003 Jan;73(1):155-64.
  6. “VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal”. Gutiérrez-Cañas I, Rodríguez-Henche N, Bolaños O, Carmena MJ, Prieto JC, Juarranz MG. Br J Pharmacol. 2003 Jul;139(5):1050-8. PDF
  7. “Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells”. Delgado M, Leceta J, Ganea D. FASEB J. 2002 Nov;16(13):1844-6.
  8. “Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases”. Delgado M, Abad C, Martínez C, Juarranz MG, Arranz A, Gomariz RP, Leceta J. J Mol Med (Berl). 2002 Jan;80(1):16-24.
  9. “Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor”. Martínez C, Abad C, Delgado M, Arranz A, Juarranz MG, Rodríguez-Henche N, Brabet P, Leceta J, Gomariz RP. Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):1053-8. PDF
  10. “Pituitary adenylate cyclase-activating polypeptide inhibits collagen-induced arthritis: an experimental immunomodulatory therapy”. Abad C, Martínez C, Leceta J, Gomariz RP, Delgado M. J Immunol. 2001 Sep 15;167(6):3182-9. PDF
  11. “Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease”.  Delgado M, Abad C, Martínez C, Leceta J, Gomariz RP. Nat Med. 2001 May;7(5):563-8.
  12. “Immunology of VIP: a review and therapeutical perspectives”. Gomariz RP, Martínez C, Abad C, Leceta J, Delgado M. Curr Pharm Des. 2001 Jan;7(2):89-111.
  13. “Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors”. Juarranz MG, Bolaños O, Gutiérrez-Cañas I, Lerner EA, Robberecht P, Carmena MJ, Prieto JC, Rodríguez-Henche N. Cell Signal. 2001 Dec;13(12):887-94.
  14. “Proline residue 280 in the second extracellular loop (EC2) of the VPAC2 receptor is essential for the receptor structure”. Vertongen P, Solano RM, Juarranz MG, Perret J, Waelbroeck M, Robberecht P. Peptides. 2001 Sep;22(9):1363-70.
  15. “Vasoactive intestinal peptide (VIP) stimulates rat prostatic epithelial cell proliferation”.  Juarranz MG, Bodega G, Prieto JC, Guijarro LG. Prostate. 2001 Jun 1;47(4):285-92.
  16. “Two basic residues of the h-VPAC1 receptor second transmembrane helix are essential for ligand binding and signal transduction”. Solano RM, Langer I, Perret J, Vertongen P, Juarranz MG, Robberecht P, Waelbroeck M. J Biol Chem. 2001 Jan 12;276(2):1084-8.